famitinib and Neuroendocrine-Tumors

Low-intermediate grade neuroendocrine tumors (NETs) are usually slow-growing cancers with a clinical course spanning few to several years managed with active surveillance, locoregional treatments, or somatostain analogs. At some point in their natural history, they develop resistance to these treatments and become more aggressive. Chemotherapy offers only limited therapeutic benefit and any evidence is based on small trials or retrospective studies. The significant progress in molecular biology shed light on the significant role of PI3K/Akt/mTOR pathway and angiogenesis in NETs, while the success of everolimus and sunitinib in landmark clinical trials opened new avenues in the discovery of effective treatments. Ongoing and planned pivotal studies testing newer agents targeting other pathways are underway. In addition to providing better treatment options, these drugs also broadened our understanding of the biology of these tumors. Biomarkers are eagerly needed with the scope of personalizing future treatment.

Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Grading; Neovascularization, Pathologic; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Signal Transduction; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins